Physician profile
Malika Tuli
NPI 1659303444
$6,465.28
in general payments reported to CMS, 2019-2025
34 companies · $736 in 2025
The $736 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,265 · 2020: $303 · 2021: $838 · 2022: $1,397 · 2023: $1,089 · 2024: $837 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,661.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,634.34 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Novartis Pharmaceuticals Corporation | $1,108.59 | 2019-2025 | |
| Janssen Biotech, INC. | $334.86 | 2021-2024 | Simponi, Simponi Aria, Stelara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $295.34 | 2019-2025 | Jublia, Arazlo, Duobrii |
| Pfizer INC. | $237.24 | 2019-2023 | |
| Ucb, INC. | $205.51 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $189.59 | 2019-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $161.33 | 2019-2023 | Dupixent |
| Genzyme Corporation | $158.82 | 2019-2024 | |
| Galderma Laboratories, L.P. | $152.46 | 2019-2024 | |
| Leo Pharma INC. | $149.40 | 2019-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $144.18 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $119.16 | 2019-2023 | Taltz |
| Organogenesis INC. | $103.99 | 2021-2023 | Puraply |
| Incyte Corporation | $72.76 | 2023-2025 | Opzelura |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $64.35 | 2022-2024 | Seysara |
| Mayne Pharma Commercial LLC | $28.90 | 2019-2023 | |
| Medimetriks Pharmaceuticals, INC. | $28.40 | 2019 | |
| Amgen INC. | $27.10 | 2023 | Otezla |
| Vyne Pharmaceuticals INC. | $26.79 | 2020-2021 | |
| Kerecis Limited | $25.48 | 2022 | |
| Aclaris Therapeutics, INC. | $21.21 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.48 | 2025 | Acthar |
| Journey Medical Corporation | $17.31 | 2022 | |
| Dermavant Sciences, INC. | $16.72 | 2023 | Vtama |
| Allergan, INC. | $15.42 | 2019 | |
| Nabriva Therapeutics, Plc | $15.04 | 2022 | |
| Strata Skin Sciences, INC. | $14.54 | 2024 | Xtrac |
| Arcutis Biotherapeutics, INC. | $14.47 | 2024 | Zoryve |
| Melinta Therapeutics, LLC | $13.80 | 2019 | |
| Encore Dermatology INC. | $12.88 | 2020 | |
| Mission Pharmacal Company | $12.69 | 2019 | |
| Dermira, INC. | $11.86 | 2019 | |
| Biofrontera INC. | $10.27 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malika Tuli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.